findmyKOL

Giuseppe Giaccone, MD, PhD

Enriched profile

Chief of Thoracic Oncology and Associate Director for Clinical Research, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine / NewYork-Presbyterian Hospital · Weill Cornell Medicine

ORCID↗NPI↗
Region🇺🇸 Bethesda, MD · Northeast · United StatesSpecialtyHematology / OncologyFocusLung Cancer Treatments and Mutations+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Giuseppe Giaccone is Chief of Thoracic Oncology and Associate Director for Clinical Research, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine / NewYork-Presbyterian Hospital at Weill Cornell Medicine. OpenAlex indexes 1,118 publications with 74,199 citations (h-index 130); ClinicalTrials.gov lists 19 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Hematology / Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Giuseppe Giaccone is Chief of Thoracic Oncology and Associate Director for Clinical Research, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine / NewYork-Presbyterian Hospital. The public record shows 1,118 publications with 74,199 citations (h-index 130), centered on Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Myasthenia Gravis and Thymoma. It also documents an investigator role on 19 registered clinical trials, industry payments reported by 6 companies.

  • Top research focus: Lung Cancer Treatments and Mutations
  • 19 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 6 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lung Cancer (NSCLC/SCLC)13 trialsSmall Cell Lung Carcinoma3 trialsThymoma2 trialsMesothelioma, Malignant1 trialMesothelioma1 trialBreast Cancer1 trialThymus Neoplasms1 trial

Research focus

OpenAlex concept fingerprint
Lung Cancer Treatments and MutationsLung Cancer Research StudiesMyasthenia Gravis and ThymomaLung Cancer Diagnosis and TreatmentCancer therapeutics and mechanisms

Drugs & molecules

across trials, industry payments and publications
Ryzneutageneric · Efbemalenograstim alfaClinical trials—Industry payments6Publications—Datrowaygeneric · Datopotamab deruxtecanClinical trials—Industry payments1Publications—Lenvimageneric · LenvatinibClinical trials—Industry payments1Publications—
3 more drug records behind the reveal.Reveal →

Works with

trial sponsors and companies reporting payments
Acrotech Biopharma Inc.Clinical trials—Industry payments9National Cancer Institute (NCI)Clinical trials7Industry payments—European Organisation for Research and Treatment of Cancer - EORTCClinical trials6Industry payments—
10 more company records behind the reveal.Reveal →

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,118publications

Distinct works indexed by OpenAlex, matched via ORCID.

74,199citations

Total citations across indexed works.

130h-index

Hirsch index (OpenAlex). i10-index 600.

Clinical & industry

trials, payments and federal funding
19clinical trials

Investigator role on registered studies.

View trials ↓
6companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 19 registered studies on ClinicalTrials.gov. The most recent:

16 more trial records behind the reveal.Reveal →

Industry payments

Updated 27 Aug 2026

6 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

4 more payment records behind the reveal.Reveal →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2021)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    100%
    Opioid Agonist100%
    Oxycodone-Acetaminophen100%
    Part D<11 patients
Where care is delivered (Part B)64.6% facility · 35.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Congress activity

Updated 27 Aug 2026

132 congress contributions (1999–2023) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:

129 more congress records behind the reveal.Reveal →

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

None on file yet. We only list publications we can confidently match to this person. Why? →

Most-cited works

by citation count (OpenAlex)
  1. 01
    The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
    4,664 citations2016
    doi.org ↗
  2. 02
    Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
    2,888 citations2003
    doi.org ↗
  3. 03
    Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
    1,750 citations2014
    doi.org ↗
  4. 04
    Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
    1,720 citations2004
    doi.org ↗
  5. 05
    Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
    1,715 citations2004
    doi.org ↗
1,113 more cited works behind the reveal.Reveal →

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Arun Rajan115Herbert M. Pinedo75Anish Thomas65
37 more collaborators behind the reveal.Reveal →

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/giuseppe-giaccone-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • ResearchGate

    researchgate.net/scientific-contributions/Giuseppe-Giaccone-2200333763

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
  • LinkedIn

    linkedin.com/in/giuseppe-giaccone-8955696a

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗

Mentions by others

where others cite or feature them
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • PhD

    Vrije University, Amsterdam, Netherlands

    1995
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
  • MD (cum laude)

    University of Turin Medical School, Italy

    1980
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org ↗
  • Board certified

    Hematology & Oncology (Internal Medicine)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗

Editorial & leadership roles

journal and society appointments
  • Chair

    EORTC Lung Cancer Cooperative Group (1993-2000); board member, EORTC

    2000
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gumc.georgetown.edu ↗
  • Director

    Thoracic Medical Oncology Section and Phase I Program, Weill Cornell Medicine

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mesothelioma.net ↗
  • President

    TAT (Targeted Anticancer Therapies) series of symposia

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gumc.georgetown.edu ↗

Awards & honors

honors on the public record
  • NDDO Honorary Award

    New Drug Development Office Foundation

    2011
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gumc.georgetown.edu ↗
  • NCI Director's Award

    National Cancer Institute

    2010
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gumc.georgetown.edu ↗
  • Daniel C. Ihde Memorial Lecture Award

    National Cancer Institute

    2009
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gumc.georgetown.edu ↗

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.